10X Genomics Closes $55.5 Million Series B Round
News Jan 13, 2015
10X Genomics has raised $55.5 Million in its Series B financing.
Foresite Capital Management led the B round and was joined by the Series A lead, Venrock, as well as new and existing investors, including Paladin Capital Group and funds managed by Morgan Stanley Investment Management. To date, the company has raised a total of more than $80M.
“10X Genomics' innovative, orthogonal approach makes use of the current installed base of sequencers to fulfil the promise of Next Generation Sequencing,” said Bryan Roberts, Partner at Venrock. “The company has made amazing progress and, in 2015, will allow customers to realize a decade's worth of promises based on fundamentally and holistically advancing the field of sequencing.”
The Company is led by founder and CEO Serge Saxonov, PhD, a founding architect of 23andMe, along with the company’s other founders, CSO Ben Hindson, PhD, and CTO Kevin Ness, PhD, all of whom previously were senior executives at Quantalife, Inc. Along with Chairman John Stuelpnagel, DVM, a co-founder and the first CEO of Illumina, the Company has assembled a management team of seasoned veterans of the genomics and sequencing industries.
“I am excited to be working with such a passionate, multidisciplinary team as we advance our technologies in high throughput picoscale reaction systems and computational genomics” said Dr. Saxonov.
10X Genomics is commercializing a new genomics platform that will change the definition of sequencing. While bringing unprecedented access to sequence data, current sequencing technology leaves a significant amount of critical genetic information inaccessible. 10X Genomics’ platform complements and upgrades existing short read sequencers to deliver long-range contextual information, including haplotyping, structural variation, and de novo assembly.
"The genome is complex and much of this complexity is lost or inaccessible using available sequencing technologies,” said Dr. Stuelpnagel. “I am excited about the platform that 10X Genomics has developed which captures this important genomic information, thereby increasing the value of sequencing."
Dr. Saxonov will present at the J.P. Morgan Healthcare Conference on January 14, 2015. 10X Genomics will unveil its innovative genomics platform at Advances in Genome Biology & Technology (AGBT) in February.
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.